Manufacturer of Controlled Substances; Notice of Registration, 27350-27351 [E9-13358]
Download as PDF
<![CDATA[
27350
Federal Register / Vol. 74, No. 109 / Tuesday, June 9, 2009 / Notices
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: June 3, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–13354 Filed 6–8–09; 8:45 am]
Drug
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 18, 2009,
Norac Inc., 405 S. Motor Avenue, P.O.
Box 577, Azusa, California 91702–3232,
made application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Nabilone (7379), a basic class of
controlled substance listed in schedule
II.
The company plans to manufacture
bulk controlled substances for use in
product development and for
distribution to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such a substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than August 10, 2009.
Dated: June 3, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–13351 Filed 6–8–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated January 9, 2009, and
published in the Federal Register on
January 21, 2009, (74 FR 3642), Johnson
Matthey Inc., Custom Pharmaceuticals
Department, 2003 Nolte Drive, West
VerDate Nov<24>2008
14:45 Jun 08, 2009
Jkt 217001
Deptford, New Jersey 08066–1742, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedules I and II:
Schedule
Tetrahydrocannabinols (7370) .....
Dihydromorphine (9145) ...............
Difenoxin (9168) ...........................
Propiram (9649) ...........................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Nabilone (7379) ............................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Morphine (9300) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Johnson Matthey Inc. to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Johnson Matthey Inc. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: June 3, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–13355 Filed 6–8–09; 8:45 am]
BILLING CODE 4410–09–P
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated January 9, 2009, and
published in the Federal Register on
January 21, 2009, (74 FR 3643), Organix
Inc., 240 Salem Street, Woburn,
Massachusetts 01801, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the basic classes
of controlled substances listed in
schedules I and II:
Drug
Tetrahydrocannabinols (7370) .....
Cocaine (9041) .............................
Schedule
I
II
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers for research
purposes.
No comments or objections have been
received. DEA has considered the
factors in 21 USC 823(a) and determined
that the registration of Organix Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Organix Inc. to ensure that
the company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: June 3, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–13359 Filed 6–8–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated February 13, 2009,
and published in the Federal Register
on February 20, 2009, (74 FR 7924),
Sigma Aldrich Research Biochemicals,
Inc., 1–3 Strathmore Road, Natick,
E:\FR\FM\09JNN1.SGM
09JNN1
Federal Register / Vol. 74, No. 109 / Tuesday, June 9, 2009 / Notices
27351
Aldrich Research Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Schedule
Massachusetts 01760–2447, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedules I and II:
Drug
Schedule
Cathinone (1235) ..........................
Methcathinone (1237) ..................
Aminorex (1585) ...........................
Gamma
Hydroxybutyric
Acid
(2010).
Alpha-ethyltryptamine (7249) .......
Lysergic acid diethylamide (7315)
Tetrahydrocannabinols (7370) .....
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
2,5-Dimethoxyamphetamine
(7396).
3,4-Methylenedioxyamphetamine
(7400).
N-Hydroxy-3,4methylenedioxyamphetamine
(7402).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4Methylenedioxymethamphetamine (MDMA) (7405).
Psilocybin (7437) ..........................
5-Methoxy-N,Ndiisopropyltryptamine (7439).
1-[1-(2Thienyl)cyclohexyl]piperidine
(TCP) (7470).
1-Benzylpiperazine (BZP) (7493)
Heroin (9200) ...............................
Normorphine (9313) .....................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Nabilone (7379) ............................
1-Phenylcyclohexylamine (7460)
Phencyclidine (7471) ....................
Cocaine (9041) .............................
Codeine (9050) .............................
Diprenorphine (9058) ...................
Ecgonine (9180) ...........................
Levomethorphan (9210) ...............
Levorphanol (9220) ......................
Meperidine (9230) ........................
Metazocine (9240) ........................
Methadone (9250) ........................
Morphine (9300) ...........................
Thebaine (9333) ...........................
Levo-alphacetylmethadol (9648) ..
Carfentanil (9743) .........................
Fentanyl (9801) ............................
I
I
I
I
I
I
I
I
Dated: June 3, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–13358 Filed 6–8–09; 8:45 am]
I
I
BILLING CODE 4410–09–P
I
I
DEPARTMENT OF JUSTICE
I
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
I
By Notice dated January 9, 2009, and
published in the Federal Register on
January 21, 2009 (74 FR 3643),
Mallinckrodt Inc., 3600 North Second
Street, St. Louis, Missouri 63147, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedules I and II:
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Drug
The company plans to manufacture
reference standards.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Sigma Aldrich Research Biochemicals,
Inc. to manufacture the listed basic
classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated Sigma
VerDate Nov<24>2008
14:45 Jun 08, 2009
Jkt 217001
Schedule
Tetrahydrocannabinols (7370) .....
Codeine-N-oxide (9053) ...............
Dihydromorphine (9145) ...............
Difenoxin (9168) ...........................
Morphine-N-oxide (9307) .............
Normorphine (9313) .....................
Norlevorphanol (9634) ..................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Methylphenidate (1724) ................
Nabilone (7379) ............................
Codeine (9050) .............................
Diprenorphine (9058) ...................
Etorphine HCL (9059) ..................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Levorphanol (9220) ......................
Meperidine (9230) ........................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Metopon (9260) ............................
Dextropropoxyphene, bulk (9273)
Morphine (9300) ...........................
Oripavine (9330) ...........................
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Drug
Thebaine (9333) ...........................
Opium extracts (9610) ..................
Opium fluid extract (9620) ............
Opium tincture (9630) ..................
Opium, powdered (9639) .............
Opium, granulated (9640) ............
Levo-alphacetylmethadol (9648) ..
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
II
II
II
II
II
II
II
II
II
II
II
II
II
The firm plans to manufacture the
listed controlled substances for internal
use and for sale to other companies.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Mallinckrodt Inc. to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Mallinckrodt Inc. to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: June 3, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–13356 Filed 6–8–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Employment and Training
Administration
[TA–W–65,865]
Seel Tool and Die, St. Marys, PA;
Notice of Termination of Investigation
Pursuant to Section 221 of the Trade
Act of 1974, as amended, an
investigation was initiated on April 29,
2009, in response to a petition filed on
behalf of workers of Seel Tool and Die,
St. Marys, Pennsylvania.
The petitioner has requested that the
petition be withdrawn. Consequently,
the investigation has been terminated.
E:\FR\FM\09JNN1.SGM
09JNN1
]]>Agencies
[Federal Register Volume 74, Number 109 (Tuesday, June 9, 2009)]
[Notices]
[Pages 27350-27351]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-13358]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated February 13, 2009, and published in the Federal
Register on February 20, 2009, (74 FR 7924), Sigma Aldrich Research
Biochemicals, Inc., 1-3 Strathmore Road, Natick,
[[Page 27351]]
Massachusetts 01760-2447, made application by renewal to the Drug
Enforcement Administration (DEA) to be registered as a bulk
manufacturer of the basic classes of controlled substances listed in
schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Cathinone (1235)........................... I
Methcathinone (1237)....................... I
Aminorex (1585)............................ I
Gamma Hydroxybutyric Acid (2010)........... I
Alpha-ethyltryptamine (7249)............... I
Lysergic acid diethylamide (7315).......... I
Tetrahydrocannabinols (7370)............... I
4-Bromo-2,5-dimethoxyamphetamine (7391).... I
4-Bromo-2,5-dimethoxyphenethylamine (7392). I
2,5-Dimethoxyamphetamine (7396)............ I
3,4-Methylenedioxyamphetamine (7400)....... I
N-Hydroxy-3,4-methylenedioxyamphetamine I
(7402).
3,4-Methylenedioxy-N-ethylamphetamine I
(7404).
3,4-Methylenedioxymethamphetamine (MDMA) I
(7405).
Psilocybin (7437).......................... I
5-Methoxy-N,N-diisopropyltryptamine (7439). I
1-[1-(2-Thienyl)cyclohexyl]piperidine (TCP) I
(7470).
1-Benzylpiperazine (BZP) (7493)............ I
Heroin (9200).............................. I
Normorphine (9313)......................... I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Nabilone (7379)............................ II
1-Phenylcyclohexylamine (7460)............. II
Phencyclidine (7471)....................... II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Diprenorphine (9058)....................... II
Ecgonine (9180)............................ II
Levomethorphan (9210)...................... II
Levorphanol (9220)......................... II
Meperidine (9230).......................... II
Metazocine (9240).......................... II
Methadone (9250)........................... II
Morphine (9300)............................ II
Thebaine (9333)............................ II
Levo-alphacetylmethadol (9648)............. II
Carfentanil (9743)......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture reference standards.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Sigma Aldrich Research Biochemicals, Inc. to manufacture the listed
basic classes of controlled substances is consistent with the public
interest at this time. DEA has investigated Sigma Aldrich Research Inc.
to ensure that the company's registration is consistent with the public
interest. The investigation has included inspection and testing of the
company's physical security systems, verification of the company's
compliance with State and local laws, and a review of the company's
background and history. Therefore, pursuant to 21 U.S.C. 823, and in
accordance with 21 CFR 1301.33, the above named company is granted
registration as a bulk manufacturer of the basic class of controlled
substance listed.
Dated: June 3, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E9-13358 Filed 6-8-09; 8:45 am]
BILLING CODE 4410-09-P
